Corcept Therapeut…
USUSDCorcept Therapeutics Incorporated (LSE:0I3Q) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- corcept.com
- Investor Relations
- ir.corcept.com/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- Menlo Park, United States
- CEO
- Joseph K. Belanoff
- Mitarbeiter
- 730
- Gegründet
- 1998
- Ausstehende Aktien
- 108.1 Mio. Stand 2026-07-22
- Streubesitz
- 96.47 Mio.
- Marktkapitalisierung
- 12.4 Mrd. USD
- Insider
- 11.47%
- Institutionelle Anleger
- 76.86%
- Branche (SIC)
- Pharmaceutical Preparations
- ISIN
- US2183521028
- LEI
- 529900EO9LUTFMZ7FF90
- FCF
- 107 Mio. USD
- Schulden
- 0 USDNettoliquidität
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
- NAV
Beschreibung
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Blackrock Inc. | 11.5% | 12.43 Mio. | 2026-06-30 |
| Ingalls & Snyder LLC | 7.34% | 7.93 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 5.39% | 5.82 Mio. | 2026-08-31 |
| BAKER GEORGE LEONARD JR.… | ≈5.14% | 5.55 Mio. | 2026-03-17 |
| Renaissance Technologies… | 4.87% | 5.26 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.67% | 5.04 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 3.86% | 4.17 Mio. | 2026-06-30 |
| Parallel Advisors, LLC | 3.67% | 3.96 Mio. | 2026-06-30 |
| FMR, LLC | 3.09% | 3.34 Mio. | 2026-06-30 |
| State Street Corporation | 3.03% | 3.28 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.68% | 2.89 Mio. | 2026-06-30 |
| AQR Capital Management,… | 2.39% | 2.58 Mio. | 2026-06-30 |
| Geode Capital Management… | 2.34% | 2.53 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.94% | 2.09 Mio. | 2026-06-30 |
| Fidelity Contrafund | 1.35% | 1.46 Mio. | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.12% | 1.21 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.01% | 1.1 Mio. | 2026-06-30 |
| First TRT Exch-Trd Fd.-F… | 0.91% | 985 377 | 2026-08-31 |
| iShares Trust-iShares S&… | 0.84% | 903 895 | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.83% | 898 881 | 2026-08-31 |
| VANGUARD TAX-MANAGED FUN… | 0.57% | 615 785 | 2026-06-30 |
| HUNT HAZEL (Officer) | ≈0.24% | 255 437 | 2026-02-09 |
| MADUCK SEAN (Officer) | ≈0.11% | 119 655 | 2026-09-01 |
| ROBB GARY CHARLES (Offic… | ≈0.07% | 74 343 | 2026-09-24 |
| MOKARI ATABAK (Chief Fin… | ≈0.02% | 16 304 | 2026-09-01 |
| LYON JOSEPH DOUGLAS (Chi… | ≈0.01% | 5 683 | 2026-09-14 |
| GUYER WILLIAM (Officer) | ≈0% | 4 313 | 2026-09-01 |
| BELANOFF JOSEPH K (Chief… | — | — | 2026-06-01 |
| MAHONEY DAVID L (Directo… | — | — | 2026-08-18 |
| WILSON JAMES N (Director… | — | — | 2026-09-15 |
Mit Google Anmelden